

#6
KAY
10-23-02
attachment

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Attorney Docket No.: RTSP-0262
Inventors: Monia et al.
Serial No.: Not Yet Assigned
Filing Date: Herewith
Examiner: Not Yet Assigned
Group Art Unit: Not Yet Assigned
Title: Antisense Modulation of MEKK1 Expression

"Express Mail" Label No. EV001201162US
Date of Deposit January 18, 2002

I hereby certify that this paper is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 on the date indicated above and is addressed to the Assistant Commissioner for Patents, Box PCT, Washington, D.C. 20231.

By Jane Massey Licata
Typed Name: Jane Massey Licata, Reg. No. 32,257

Assistant Commissioner for Patents
Washington, DC 20231

Sir:

INFORMATION DISCLOSURE STATEMENT

Pursuant to 37 C.F.R. §1.56 and in accordance with 37 C.F.R. §§1.97-1.98, information relating to the above-identified application is hereby disclosed. Inclusion of information in this statement is not to be construed as an admission that this information is material as that term is defined in 37 C.F.R. §1.56(b).

(XX) In accordance with §1.97(b), since this Information Disclosure Statement is being filed either within three months of the filing date of the above-identified

application, within three months of the date of entry into the national stage of the above identified application as set forth in \$1.491, or before the mailing date of a first Office Action on the merits of the above-identified application, no additional fee is required.

- () In accordance with \$1.97(c), this Information Disclosure Statement is being filed after the period set forth in \$1.97(b) above but before the mailing date of either a Final Action under \$1.113 or a Notice of Allowance under \$1.311, therefore:

- () Certification in Accordance with \$1.97(e) is set forth below; or
- () The fee of \$180.00 as set forth in \$1.17(p) is attached.

- () In accordance with \$1.97(d), this Information Disclosure Statement is being filed after the mailing date of either a Final Action under \$1.113 or a Notice of Allowance under \$1.311 but before the payment of the Issue Fee, therefore included are: Certification in Accordance with \$1.97(e); Petition Requesting Consideration of the Information Disclosure Statement; and the fee of \$130.00 as set forth in \$1.17(i)(1).

- () Copies of each of the references listed on the attached Form PTO-1449 (modified) are enclosed herewith.

- (XX) In accordance with \$1.98(d), copies of some or all of the references listed on the attached Form PTO-1449 (modified)


are not enclosed herewith because they were previously submitted to the U.S. Patent and Trademark Office in prior application Serial No. 09/359,756, filed July 23, 1999, for which a claim for priority under 35 U.S.C. §120 has been made in the instant application.

Please charge any deficiency or credit any overpayment to Deposit Account No. 50-1619. This form is submitted in duplicate.

() The relevance of the listed references in a foreign language is as stated in the specification at pages @@.

(XX) All listed references are in the English language.

Respectfully submitted,



Jane Massey Licata
Registration No. 32,257

Date: January 18, 2002

Licata & Tyrrell P.C.
66 E. Main Street
Marlton, New Jersey 08053

(856) 810-1515

Form PTO-1449 Modified

List of Patents and Publications
Cited by Applicant
(Use several sheets if necessary)

U.S. Department of Commerce
Patent and Trademark Office

Docket No.
RTSP-0262

Serial No.
Not Yet Assigned

Applicant
Monia et al.

Filing Date
Herewith

Group
Not Yet Assigned

U. S. PATENT DOCUMENTS

Examiner		Document	Date	Name	Class	Subclass
	AA	5,405,941	5/22/95	Johnson et al.	530	350
	AB	6,074,861	6/13/00	Johnson	435	194
	AC	5,981,265	11/9/99	Johnson	435	254.1

FOREIGN PATENT DOCUMENTS

Examiner Initial		Document No.	Date	Country	Translation YES NO	
	AD	WO 98/54203	12-3-98	PCT	x	

EXAMINER**DATE CONSIDERED**

Sheet 01 of 03

Form PTO-1449 Modified		Docket No. RTSP-0262	Serial No. Not Yet Assigned
List of Patents and Publications Cited by Application (Use several sheets if necessary)		Applicant Monia et al.	
		Filing Date Herewith	Group Not Yet Assigned
U.S. Department of Commerce Patent and Trademark Office			
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)			
	AA	Efimova et al., Regulation of human involucrin promoter activity by a protein kinase C, Ras, MEKK1, MEK3, p38/RK, AP1 signal transduction pathway, J. Biol. Chem., 1998, 273:24387-24395	
	AB	Fuchs et al., MEKK1/JNK signaling stabilizes and activates p53, Proc. Natl. Acad. Sci. U. S. A., 1998, 95:10541-10546	
	AC	Ishizuka et al., Mast cell tumor necrosis factor alpha production is regulated by MEK kinases, Proc. Natl. Acad. Sci. U. S. A., 1997, 94:6358-6363	
	AD	Lee et al., Activation of the IkappaB alpha kinase complex by MEKK1, a kinase of the JNK pathway, Cell, 1997, 88:213-222	
	AE	Leppa et al., Differential regulation of c-Jun by ERK and JNK during PC12 cell differentiation, Embo. J., 1998, 17:4404-4413	
	AF	Meyer et al., Interaction between c-Rel and the mitogen-activated protein kinase kinase kinase 1 signaling cascade in mediating kappaB enhancer activation, J. Biol. Chem., 1996, 271:8971-8976	
	AG	Moriguchi et al., Roles of the MAP kinase cascade in vertebrates, Adv. Pharmacol., 1996, 36:121-137	
	AH	Park et al., Activation of c-Jun N-terminal kinase antagonizes an anti-apoptotic action of Bcl-2, J. Biol. Chem., 1997, 272:16725-16728	
	AI	Pomerance et al., Grb2 interaction with MEK-kinase 1 is involved in regulation of Jun-kinase activities in response to epidermal growth factor, J. Biol. Chem., 1998, 273:24301-24304	
EXAMINER		DATE CONSIDERED	

Form PTO-1449 Modified List of Patents and Publications Cited by Applicant (Use several sheets if necessary) U.S. Department of Commerce	Docket No. RTSP-0262	Serial No. Not Yet Assigned
	Applicant Monia et al.	
	Filing Date Herewith	Group Not Yet Assigned

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

	AJ	Shiah et al., "Activation of c-Hun NH2-terminal kinase and subsequent CPP32/Yama during topoisomerase inhibitor beta-lapachone-induced apoptosis through an oxidation-dependent pathway", <i>Cancer Res.</i> 1999 59:391-398
	AK	Su et al., "Mitogen-activated protein kinase cascades and regulation of gene expression", <i>Curr. Opin. Immunol.</i> 1996 8:402-0411
	AL	Widmann et al., "Potentiation of apoptosis by low dose stress stimuli in cells expressing activated MEK kinase 1", <i>Oncogene</i> 1997 15:2439-2447
	AM	Xu et al., "MEKK1 binds directly to the c-Jun N-terminal kinases/stress-activated protein kinases", <i>J. Biol. Chem.</i> 1997 272:32056-32060
	AN	Agrawal S., "Antisense Research and Application-Antisense Oligonucleotides:A New Therapeutic Principle", <i>Chemical Reviews</i> 1990 90(4):542-584
	AO	Crooke S.T., "Basic Principles of Antisense Therapeutics" In:Antisense Research and Application CHAPTER 1 1998
	AP	Branch A.D., "A good antisense molecule is hard to find", <i>TIBS</i> 1998 45-50
	AQ	Milner et al., "Selecting effective antisense reagents on combinatorial oligonucleotide arrays", <i>Nature Biotech.</i> 1997 15:537-541

EXAMINER	DATE CONSIDERED
-----------------	------------------------